Form 4 for PRLD Prelude Therapeutics Inc
Accepted 2022-04-04 00:00:00 ET · period of report 2022-03-31 · accession 0001209191-22-022524 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-04 | 2022-03-31 | PRLD | Combs Andrew | EVP, Head of Chemistry | M - OptEx | $1.89 | +36.1K | 304.4K | +13% | +$68.2K |
| D | 2022-04-04 | 2022-04-01 | PRLD | Combs Andrew | EVP, Head of Chemistry | M - OptEx | $0.00 | -36.1K | 50.4K | -42% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | M | A | 36,062 | $1.89 | 304,442 | D | — | — | (F1) Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-04-01 | M | D | 36,062 | $0.00 | 50,397 | D | $1.89 · — to 2030-03-26 | 36,062 Common Stock | (F2) The stock option vested as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |